Actively Recruiting
Predictors for Chronic Thromboembolic Pulmonary Hypertension After Pulmonary Embolism Episode
Led by Ester Ashraf Faried Beshay · Updated on 2025-12-01
100
Participants Needed
1
Research Sites
8 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to detect and predict the occurrence of chronic thromboembolic pulmonary hypertension (CTEPH) in patients who have experienced a pulmonary embolism. CTEPH is a progressive condition caused by chronic blockage of major lung arteries by organized blood clots and falls under pulmonary hypertension due to artery obstruction. Early diagnosis is important as CTEPH is potentially curable, but symptoms are often non-specific or absent in early stages, making detection challenging. The study also considers post-pulmonary embolism syndrome, which includes symptoms like breathlessness, anxiety, and chest pain that affect quality of life. The study monitors symptomatic patients after a pulmonary embolism episode over three years. It uses transthoracic Doppler echocardiography to assess right ventricular function through measures such as peak tricuspid regurgitation velocity, right ventricle to left ventricle diameter ratio, interventricular septum flattening, right ventricular acceleration time, and inferior vena cava diameter changes. These echocardiographic signs help evaluate the likelihood of pulmonary hypertension and right heart function impairments. Participants will be evaluated through echocardiography and clinical assessments over three years to measure the incidence of CTEPH and right ventricle dysfunction. Researchers will track several heart function parameters and symptoms related to pulmonary hypertension. The study also observes secondary effects like post-thrombotic syndrome and functional limitations. The total participation duration is up to three years, during which patient symptoms, heart function, and other related health indicators are regularly monitored to better understand the development of CTEPH.
CONDITIONS
Brief Title
Chronic Thromboembolic Pulmonary Hypertension After Pulmonary Embolism
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with acute pulmonary embolism
- Aged between 18 and 80 years
- Pulmonary Embolism Severity Index (PESI) class III to V or simplified PESI score of 1 or higher
You will not qualify if you...
- Secondary causes of pulmonary hypertension
- Severe kidney injury (eGFR less than or equal to 30 mg/dl/1.7 m2)
- Liver disease
- Contraindication to anticoagulation therapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 3 years
Participants are monitored to assess the incidence of chronic thromboembolic pulmonary hypertension and right ventricular dysfunction after a pulmonary embolism episode.
Periodic visits over 3 years to assess heart and lung function
Trial Site Locations
Total: 1 location
1
Assiut University
Asyut, Egypt, AssiutU
Actively Recruiting
Research Team
E
Ester A Faried, resident
A
Aly M Tohamy, Professor
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here